Ankylosing spondylitis (AS) is a progressive, incurable rheumatologic disease with worldwide prevalence of 0.1-0.5%. Since January 2012, the Brazilian Agency for Supplementary Healthcare (ANS -Agência Nacional de Saúde Suplementar) declared the coverage of intravenous biological drugs (BD) mandatory for patients with AS, rheumatoid arthritis, psoriatic arthritis and Crohn's disease in the private healthcare system (PHS). This study presents real-word data on the patterns-of-care for AS in Brazilian PHS.
CONCLUSION:
The choice of biological drugs followed the international guidelines for AS. However, almost half the patients could not have diagnosis of AS confirmed, even tough some were already on 2nd or 3rd line therapy with BD. PHS must emphasize the correct use of diagnostic criteria before patients are put on unnecessary treatment with BD. Evidências -Kantar Health, Campinas, São Paulo, Brazil Ankylosing Spondylitis (AS) is a progressive and disabling rheumatologic disease, which affects mainly the sacroiliac joint, but that can also affect the spine and other locations. At present, there is no known cure for AS. [1] [2] [3] Some treatments, such as immune biological drugs (BD), recommended by international as well as local specialty societies can decrease the level of disease activity and improve the quality of life od patients. [4] [5] [6] Although effective, treatment with BD is costly. 7, 8 This type of treatment was determined for mandatory coverage by Brazilian Private Healthcare Plans (PHP) such as health insurance companies, HMOs, and others, due to a recommendation from the regulatory organ issued in January of 2012. BDs were indicated for selected patients, with moderate to severe diseases, which were refractory to anti-inflammatory medications.
INTRODUCTION
We analyzed requests for BD in the treatment of AS from almost all regions of Brazil, and identified a predominance of female patients and anti-TNF class drugs.
Likely misdiagnoses were found in an expressive proportion of cases, indicating the need for CME programs and a more meticulous control from PHPs during the BD request analysis.
Further studies are warranted to explore, confirm and better explain these findings.
The predominance of females was unexpected, since AS is more prevalent and severe among males.
10,11
Nevertheless, Brazilian study has shown that women had a worse quality of life regarding the disease when compared to men, 12 and may therefore, quickly migrate from anti-inflammatory drugs to BD. On the other hand, a Swedish trial points to a different pattern, in which males would more prone to receive BD.
11
Some researchers also correlate the female gender with a higher rate of failure after the use of BD from anti-TNF class, which suggests that they may indeed respond in a different way to treatment.
13
The prevalence of anti-TNF drugs found here corresponds to guidelines published by specialty societies and the manufacturer's recommendations in Brazil. [4] [5] [6] It is also consistent with findings in similar studies. The lack of solid information on diagnosis and the fact that there were other, more probable diagnoses for an expressive part of the patients was perplexing. This facts are corroborated by cases with magnetic resonances showing normal sacroiliac joint and by elderly patients "recently" diagnosed with AS (according to current criteria, patients over 45 years-old would not be eligible for such diagnosis).
1,14
Conflict of interests regarding direct or indirect benefits derived from the prescription of BD, as well as flaws in the formation and education of healthcare professionals may explain some of this situation. It is imperative that continuous medical education (CME) programs are established to cover this area. Also, physicians must be educated on which documents are mandatory to request treatment with BD from a PHP.
On the other hand, PHPs must be attentive to the importance of a confirmed AS diagnosis not only in the moment of the first BD request, but also in the event of treatment failure (consider the possibility of a misdiagnosis).
Larger studies are needed to confirm these findings within the Brazilian PHS. 
DISCUSSION

RESULTS
During the study timeframe, we retrieved 46 patients for whom AS diagnosis was appointed for BD reimbursement purposes by their physicians. Figure 1 summarizes our findings.
• Primary sacroiliitis (17.4%) Primary degenerative disease of the spine without sacroiliitis (3%) Unspecific lumbar pain (4.3%) Enteropathic arthropathy (4.3%)
Reiter's Syndrome (2.2%) Unspecific seronegative arthropathy (2.2%)
We found 16 males (24.8%) and 30 females (65.2%), with mean age of 43.7 years (varying from 16 to 74 years).
We received requests regarding patients from the Northeast, Southeast, Central-West and South Regions.
The most requested drugs were, in decreasing order: infliximab (39.1%), adalimumab (21.7%), golimumab (19.6%), etanercept (17.4%) and rituximab (2.2%).
Most patients were on first-line treatment with BD (73.9%), while 23.9% were on second-line and 2.2% in third-line.
Considering patients on second or third-lines, the alleged reasons for drug change were: unsatisfactory response (75%) or due to adverse events (25%).
Considering the information sent for analysis, the alleged AS diagnosis could not be confirmed in all the cases.
AS was the likeliest diagnosis in 52.2% of cases. In 13% of cases, the information was insufficient to establish a diagnosis.
In the other 34.8% of the cases, the most likely diagnoses were (see 
